The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

verogen.com

Founded Year

2017

Stage

Loan | Alive

Total Raised

$680K

Last Raised

$680K | 2 yrs ago

About Verogen

Verogen provides forensic sequencing technology to criminal casework and other forensic applications.

Verogen Headquarter Location

11111 Flintkote Avenue

San Diego, California, 92121,

United States

+1 858 285 4101

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Verogen News

Verogen Introduces 'Accessible' NGS Workflow for Typical Forensic Labs

Nov 27, 2021

May 05, 2021 Verogen is debuting an affordable entry point to NGS on the MiSeq FGx Sequencing System with the commercial launch of the ForenSeq MainstAY Workflow. The kit targets the core autosomal and Y-STR loci accepted by global databases, minimizing the need to validate additional markers. With two kit sizes and support for volume sequencing, this workflow will empower the forensic community with a cost-effective alternative to CE-based STR typing that is easy to adopt. Verogen is also pleased to announce that it is partnering with Eurofins Forensic Services, the European leader in forensics sciences, to implement NGS into routine casework. “ForenSeq MainstAY will support volume casework and sexual assault cases. By combining the high-throughput of this kit with the extensibility and speed of the MiSeq FGx System, forensic laboratories can finally bring next-generation sequencing in-house,” said Brett Williams, Chief Executive Officer at Verogen. “ForenSeq MainstAY advances our commitment to expand access to NGS with standardized, globally-distributable tools so all forensic laboratories can benefit from the capabilities that sequencing enables, without extending their budgets or significantly changing their CE-based workflows.” “We are constantly looking at ways to provide new forensic insights to our customers,” Stanislas Le Chevalier, National Division Leader of Eurofins Forensics, France, commented. “This partnership allows us to leverage Verogen technology and harness the expertise of the trusted forensic leaders across the Eurofins network. Together, we aim to demonstrate the capability of the MiSeq FGx Sequencing System as a cost-effective alternative to classical capillary electrophoresis technologies in forensic genetics. It is the belief of Eurofins Forensics and its external partners, such as Professor Dieter Deforce at the University of Gent, that this program will be the key to applying the power of NGS to both routine casework and complex phenotyping.” Alexandra Schlenck, Managing Director of the Institut Français des Empreintes Génétiques (IFEG) Nantes and a recognized expert in forensic DNA typing, announced that IFEG would pilot and promote this project within Eurofins, to validate the high-throughput platform that will deliver hundreds of tests per week. The goal of the three-phase pilot is to create an implementation model that can be easily replicated within Eurofins Forensics and its partners.

Nov 20, 2021
About Verogen

Verogen Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Verogen Rank

  • When was Verogen founded?

    Verogen was founded in 2017.

  • Where is Verogen's headquarters?

    Verogen's headquarters is located at 11111 Flintkote Avenue, San Diego.

  • What is Verogen's latest funding round?

    Verogen's latest funding round is Loan.

  • How much did Verogen raise?

    Verogen raised a total of $680K.

  • Who are the investors of Verogen?

    Investors of Verogen include Paycheck Protection Program and Illumina.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.